{"retracted":true,"title":"Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.","url":"http://doi.org/10.1038/sj.bjc.6605972","journal":"British journal of cancer","update":"retracted"}
